Overview

A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar levels. Side effects and tolerability will be documented. The study will last at least 18 days, not including screening. Screening is required within 4 weeks prior to the start of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc